Optimal role of temozolomide in the treatment of malignant gliomas

Roger Stupp; Martin J. van den Bent; Monika E. Hegi

doi:10.1007/s11910-005-0047-7

Optimal role of temozolomide in the treatment of malignant gliomas

Roger Stupp^*, Martin J. van den Bent, Monika E. Hegi

^*Corresponding author for this work

Neurological Surgery

Research output: Contribution to journal › Review article › peer-review

163 Scopus citations

Abstract

Temozolomide (TMZ) is an alkylating agent that was approved for anaplastic astrocytoma and glioblastoma. Its role in the treatment of recurrent disease has been confirmed, and more importantly, alternative treatment schedules and combination regimens have been developed. A recent phase III trial has demonstrated a survival advantage for concomitant TMZ administration with radiotherapy in patients with newly diagnosed glioblastoma. Molecular studies suggest a strong predictive role of the DNA repair enzyme O6-methyl-guanine-DNA-methyl-transferase (MGMT) and outcome of TMZ-based chemotherapy. This review summarizes the current knowledge, highlights approved and nonapproved indications, and describes molecular studies that may allow us to identify the patients most likely to benefit from this treatment.

Original language	English (US)
Pages (from-to)	198-206
Number of pages	9
Journal	Current neurology and neuroscience reports
Volume	5
Issue number	3
DOIs	https://doi.org/10.1007/s11910-005-0047-7
State	Published - May 2005

ASJC Scopus subject areas

Neuroscience(all)
Clinical Neurology

Access to Document

10.1007/s11910-005-0047-7

Cite this

@article{c19b83dbc5b548fd8251d4e857c35818,

title = "Optimal role of temozolomide in the treatment of malignant gliomas",

abstract = "Temozolomide (TMZ) is an alkylating agent that was approved for anaplastic astrocytoma and glioblastoma. Its role in the treatment of recurrent disease has been confirmed, and more importantly, alternative treatment schedules and combination regimens have been developed. A recent phase III trial has demonstrated a survival advantage for concomitant TMZ administration with radiotherapy in patients with newly diagnosed glioblastoma. Molecular studies suggest a strong predictive role of the DNA repair enzyme O6-methyl-guanine-DNA-methyl-transferase (MGMT) and outcome of TMZ-based chemotherapy. This review summarizes the current knowledge, highlights approved and nonapproved indications, and describes molecular studies that may allow us to identify the patients most likely to benefit from this treatment.",

author = "Roger Stupp and {van den Bent}, {Martin J.} and Hegi, {Monika E.}",

year = "2005",

month = may,

doi = "10.1007/s11910-005-0047-7",

language = "English (US)",

volume = "5",

pages = "198--206",

journal = "Current neurology and neuroscience reports",

issn = "1528-4042",

publisher = "Current Medicine Group",

number = "3",

}

TY - JOUR

T1 - Optimal role of temozolomide in the treatment of malignant gliomas

AU - Stupp, Roger

AU - van den Bent, Martin J.

AU - Hegi, Monika E.

PY - 2005/5

Y1 - 2005/5

N2 - Temozolomide (TMZ) is an alkylating agent that was approved for anaplastic astrocytoma and glioblastoma. Its role in the treatment of recurrent disease has been confirmed, and more importantly, alternative treatment schedules and combination regimens have been developed. A recent phase III trial has demonstrated a survival advantage for concomitant TMZ administration with radiotherapy in patients with newly diagnosed glioblastoma. Molecular studies suggest a strong predictive role of the DNA repair enzyme O6-methyl-guanine-DNA-methyl-transferase (MGMT) and outcome of TMZ-based chemotherapy. This review summarizes the current knowledge, highlights approved and nonapproved indications, and describes molecular studies that may allow us to identify the patients most likely to benefit from this treatment.

AB - Temozolomide (TMZ) is an alkylating agent that was approved for anaplastic astrocytoma and glioblastoma. Its role in the treatment of recurrent disease has been confirmed, and more importantly, alternative treatment schedules and combination regimens have been developed. A recent phase III trial has demonstrated a survival advantage for concomitant TMZ administration with radiotherapy in patients with newly diagnosed glioblastoma. Molecular studies suggest a strong predictive role of the DNA repair enzyme O6-methyl-guanine-DNA-methyl-transferase (MGMT) and outcome of TMZ-based chemotherapy. This review summarizes the current knowledge, highlights approved and nonapproved indications, and describes molecular studies that may allow us to identify the patients most likely to benefit from this treatment.

UR - http://www.scopus.com/inward/record.url?scp=21044459993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21044459993&partnerID=8YFLogxK

U2 - 10.1007/s11910-005-0047-7

DO - 10.1007/s11910-005-0047-7

M3 - Review article

C2 - 15865885

AN - SCOPUS:21044459993

SN - 1528-4042

VL - 5

SP - 198

EP - 206

JO - Current neurology and neuroscience reports

JF - Current neurology and neuroscience reports

IS - 3

ER -

Optimal role of temozolomide in the treatment of malignant gliomas

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this